Ignite Creation Date:
2024-05-06 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 12:46 PM
Study NCT ID:
NCT03536975
Status:
UNKNOWN
Last Update Posted:
2018-05-25
First Post:
2018-01-30
Brief Title:
Identify the Benefits CAREGIVERSPRO-MMD Platform Use Based on the Information and Communications Technology Dedicated to the Support and Assistance of Dyads Living With Neurocognitive Diseases and Their Primary Caregivers
Sponsor:
University Hospital Rouen
Organization:
University Hospital Rouen
Study Overview
Official Title:
Pilot Study to Identify the Benefits CAREGIVERSPRO-MMD Platform Use Based on the Information and Communications Technology Dedicated to the Support and Assistance of Dyads Living With Neurocognitive Diseases Including Persons Living With Mild Cognitive Impairment or Mild to Moderate Dementia and Their Primary Caregivers
Status:
UNKNOWN
Status Verified Date:
2018-05
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CAREGIVERSPRO
Brief Summary:
Our main goal is to test a web platform accessible by computers smartphones and tablets addressed specifically to caregivers and people with mild cognitive deterioration or mild to moderate dementia providing added value services based on social networks adapted interventions clinic strategies and gamification to improve the quality of life of caregivers and people living with dementia dyads and permitting to leave in the community as long as possible
To evaluate the platform effectiveness and impact in dementia type disease affected people and caregivers a randomized controlled parallel longitudinal is proposed The objective will be to assess during 18 months aspects related to health of individuals general aspect of health neuropsychological daily living functionalities quality of life treatment adherence comorbidities social aspects improving dyad relationship and economics cost-effectiveness of platform utilization as well as satisfaction degree and usability of platform
To evaluate the platform effectiveness and impact in dementia type disease affected people and caregivers a randomized controlled parallel longitudinal is proposed The objective will be to assess during 18 months aspects related to health of individuals general aspect of health neuropsychological daily living functionalities quality of life treatment adherence comorbidities social aspects improving dyad relationship and economics cost-effectiveness of platform utilization as well as satisfaction degree and usability of platform
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None